948 related articles for article (PubMed ID: 28333319)
1. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
Mushtaq S; Vickers A; Woodford N; Livermore DM
J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319
[TBL] [Abstract][Full Text] [Related]
2. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria.
Livermore DM; Mushtaq S; Warner M; Vickers A; Woodford N
J Antimicrob Chemother; 2017 May; 72(5):1373-1385. PubMed ID: 28158732
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK
J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338
[TBL] [Abstract][Full Text] [Related]
5. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa.
Livermore DM; Warner M; Mushtaq S
J Antimicrob Chemother; 2013 Oct; 68(10):2286-90. PubMed ID: 23696619
[TBL] [Abstract][Full Text] [Related]
6. Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters.
Mushtaq S; Woodford N; Hope R; Adkin R; Livermore DM
J Antimicrob Chemother; 2013 Jul; 68(7):1601-8. PubMed ID: 23449829
[TBL] [Abstract][Full Text] [Related]
7. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
[TBL] [Abstract][Full Text] [Related]
8. Activity of Meropenem with a Novel Broader-Spectrum β-Lactamase Inhibitor, WCK 4234, against Gram-Negative Pathogens Endemic to New York City.
Iregui A; Khan Z; Landman D; Quale J
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611363
[TBL] [Abstract][Full Text] [Related]
9. Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.
Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848013
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.
Mushtaq S; Warner M; Livermore DM
J Antimicrob Chemother; 2010 Nov; 65(11):2376-81. PubMed ID: 20801783
[TBL] [Abstract][Full Text] [Related]
11. Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres.
Khan Z; Iregui A; Landman D; Quale J
J Antimicrob Chemother; 2019 Oct; 74(10):2938-2942. PubMed ID: 31298277
[TBL] [Abstract][Full Text] [Related]
12. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.
Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N
J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202
[TBL] [Abstract][Full Text] [Related]
13. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases.
Mushtaq S; Ge Y; Livermore DM
Antimicrob Agents Chemother; 2004 Apr; 48(4):1313-9. PubMed ID: 15047535
[TBL] [Abstract][Full Text] [Related]
14. [Approach to directed therapy after knowledge of the isolate: carbapenemase-producing Enterobacteriaceae, multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii].
Martínez JA
Rev Esp Quimioter; 2016 Sep; 29 Suppl 1():31-4. PubMed ID: 27608310
[TBL] [Abstract][Full Text] [Related]
15. Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234.
Papp-Wallace KM; Nguyen NQ; Jacobs MR; Bethel CR; Barnes MD; Kumar V; Bajaksouzian S; Rudin SD; Rather PN; Bhavsar S; Ravikumar T; Deshpande PK; Patil V; Yeole R; Bhagwat SS; Patel MV; van den Akker F; Bonomo RA
J Med Chem; 2018 May; 61(9):4067-4086. PubMed ID: 29627985
[TBL] [Abstract][Full Text] [Related]
16. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.
Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289035
[TBL] [Abstract][Full Text] [Related]
17. Activity of the β-Lactamase Inhibitor LN-1-255 against Carbapenem-Hydrolyzing Class D β-Lactamases from Acinetobacter baumannii.
Vázquez-Ucha JC; Maneiro M; Martínez-Guitián M; Buynak J; Bethel CR; Bonomo RA; Bou G; Poza M; González-Bello C; Beceiro A
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807908
[TBL] [Abstract][Full Text] [Related]
18. Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City.
Lapuebla A; Abdallah M; Olafisoye O; Cortes C; Urban C; Landman D; Quale J
Antimicrob Agents Chemother; 2015 Aug; 59(8):5029-31. PubMed ID: 26014931
[TBL] [Abstract][Full Text] [Related]
19. Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae.
Livermore DM; Mushtaq S
J Antimicrob Chemother; 2013 Aug; 68(8):1825-31. PubMed ID: 23580564
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
Livermore DM; Chen HY
J Antimicrob Chemother; 1997 Sep; 40(3):335-43. PubMed ID: 9338484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
